APOE and Alzheimer disease: The most frequent pharmagenes with dysfunctional effects in AD are the follows: CES1 (96.45%), FABP2 (90.86%), ABCG2 (90.36%), CYP1B1 (82.23%), PPARG (81.73%), HTR2C (79.19%), HMGCR (73.60%), OPRM1 (69.54%), SOD2 (67.51%), VKORC1 (65.99%), HTR1A (65.48%), SLCA2 (59.90%), GABRA1 (55.33%), GSTM1 (54.82%), SLC30A8 (48.22%), MAOB (47.72%), DRD2 (45.18%), ABCB1 (44.16%), NAT2 (43.65%), AGT (42.13%), CHRNA7 (42.13%), ADRB2 (41.62%), PRKCE (41.62%), SLC22A1 (34.52%), CHAT (36.04%), CYP1A1 (31.47%), APOE (30.96%), COMT (30.96%), and GSTT1 (25.38%)(Figure 6).